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sites were vagina in 14, vagina and vulva in 4, uterine cervix in 3, and 
vulva in 2. The T stage was r2a in 2, 3a in 3, 4a in 17 and r4 in 1. The 
clinical stage was stage II in15, r stage II in 3, stage III in 4, and stage 
IV in 1. The irradiated dose was 57.6 GyE in 22 and 64 GyE in 1. 
Twelve patients were treated with DAV regime (DTIC, ACNU, VCR), 
and 8 patients were treated with IFN-β for induction and /or adjuvant 
therapy. One patient had been used IFN-β during radiotherapy. Acute 
toxicities greater than grade 2 were colitis in 4, diarrhea in 4, fecal 
incontinence in 1, malaise in 1,dermatitis radiation in 11, urinary 
frequency in 2, urinary infection in 1, urinary tract pain in 9, perineal 
pain in 10, and vaginal pain in 9. One patient who had been treated 
with concurrent IFN-β developed sepsis. The median follow-up time 
was 17 months (ranged 1 to 53 months). One case of grade 3 bowel 
reaction, one case of grade 2 bowel reaction, and one case of grade 3 
bladder reaction have been observed. Twelve patients have recurred, 
in-field in 3,marginal field in 2, regional lymph node in 4 and distant 
in 9. Ten patients were dead, two were of intercurrent disease and 
other 8 were of melanoma. The 2-year local control rate and overall 
survival rate were 80% and 56% respectively. 
Conclusions: Carbon ion radiotherapy for gynecological melanoma 
offered therapeutic effectiveness with acceptable toxicities of normal 
tissues. 
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Purpose/Objective: To investigate diffusion weighted imaging (DWI) 
as an imaging biomarker in women undergoing chemoradiation for 
vault cancers. 
Materials and Methods: From October 2008 to May, 2012 patients 
scheduled to undergo chemoradiation and vaginal brachytherapy for 
vault cancers were included. All underwentT2-Weighted (T2W) and 
DWI before chemoradiation. Gross tumor volume (GTV), lateral 
extent, apparent diffusion coefficient (ADC) and presence of regions 
of focally restricted diffusion (or intratumoral diffusion heterogeneity) 
were determined at baseline. Immediate response to chemoradiation 
was categorised as either partial or complete and long term response 
as local relapse /disease free or not. Receiver Operator 
Characteristics (ROC) curve identified thresholds of GTV and ADC that 
best predict for partial response. Data was categorized across 
identified cut off’s for univariate and cox multivariate regression 
analysis in SPSS version 15.0.  
Results: The study included 29 patients with a median follow up of 16 
months (3-35 months).The median GTV was 27 cc (3.4-110cc). Central 
and lateral disease was present in 13(44.8%) and 16 (55.2%) patients 
respectively. The median ADC was 1.1x 10 -3 mm2/sec (0.75-1.37X10 -3 
mm2/sec) and 12/29 (41.3%) patients had focal regions of restricted 
diffusion. All received concurrent chemoradiation to a dose of 50 
Gy/25#/5 weeks with concurrent cisplatin. This was followed by 
interstitial brachytherapy (20Gy/5#/3 days). Overall 16/29 (55.1%) 
patients had radiological partial response at 50 Gy. At a median follow 
up of 16 months, 20/29 (68.9%) patients were disease free and 21/29 
(72.4%) were without local recurrence. On univariate analysis bulky 
disease (81.8%vs. 35.2%; p=0.01), lateral disease extent (75% vs. 
30.7%; p=0.01) predicted for partial response at completion of 
treatment. However on multivariate analysis only ADC value >1 x10-3 
mm2/s predicted for partial response (63.1% vs 33.1%; p=0.02). On 
multivariate analysis in addition to tumour bulk (p=0.01), focal regions 
of ADC restriction were identified as an independent factor impacting 
long-term local relapse free (p=0.01) and disease free survival 
(p=0.01) 
Conclusions: Tumor ADC and intratumoral focal regions of restricted 
diffusion independently predict for partial response and reduced local 
relapse free and disease free survival in women undergoing 
chemoradiation for vault cancers. Results of the study need validation 
in larger cohort. 
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Purpose/Objective: Metastatic lymph nodes (LN) are one of the most 
important prognostic factors for cervical cancer patients (PTS). The 
standard prescribed radiotherapy dose fails to successfully control the 
nodal disease and the dose escalation with conventional techniques is 
connected with dose limiting toxicities. The aim of this study is to 
evaluate dosimetric parameters and early and late toxicities of dose 
escalated intensity modulated radiotherapy (IMRT). 
Materials and Methods: The study included cervical cancer PTS with 
PET-CT positive LN treated with escalated dose of RT with curative 
intent. The dose of 50.4 Gy (1.8 Gy daily) was prescribed to the 
elective nodal volume and gross tumor volume. In case of positive LN 
in level of the arteria Iliaca communis the dose of 45 Gy was 
prescribed to the paraaortic region and in case of involved paraaortic 
LN dose was 50.4 Gy (Phase I). Primary tumors < 4 cm in diameter 
received boost of 5.4 Gy and for those > 4 cm in diameter a boost of 9 
Gy (Phase II). PET-CTpositive LN received consecutive boost to total 
dose of 59.4 Gy, or simultaneous integrated boost (SIB) to a total dose 
of 62 Gy. IMRT was followed by 3D conformal HDR intrauterine 
brachytherapy with a single fraction of 6 Gy to a total dose of 18 Gy. 
We evaluated summed Dose Volume Histograms (DVH) data for all 
patients.Toxicities were graded according to the CTCAE v3.0. 
Results: In period between Oct. 2006 and Feb. 2012, 21 PTS with 
median age of 63 Y (range: 48-101Y) were treated. 16 PTS had tumor 
> 4cm and median number of positive LN pro patient was 3 (range: 1-5 
LN). 8 PTS were diagnosed with positive paraaortic LN. 12 PTS were 
treated with extended field RT. 14 patients received SIB and 7 
consecutive boost to the positive LN. 2 PTS received IMRT boost to 
primary tumor of 72 Gy. Median follow-up time was 25 months (range: 
5-51months). 20 PTS received concomitant weekly cisplatine 
chemotherapy. Median bladder volume was 127 cm3 (range: 20-591 
cm3) with median dose to the organ of 52 Gy. Median intestine 
volume was 1840 cm3 (range:1000-4798 cm3) with median dose to the 
organ of 21 Gy. Median rectal volume was 75 cm3 (range: 23-250 cm3) 
with median dose to the organ of 53 Gy. Median ratios of total 
structure volumes (DVH parameters of summed plans) with 
corresponding doses are showed in Table 1. Median PTV volume for 
phase I, phase II and nodal boost were 1431 cm3(range: 1037-2248 
cm3), 461 cm3 (range: 216-961cm3) and 37 cm3 (range: 5-201cm3) 
respectively. The therapy was well tolerated. We record no toxicities 
from side upper GIT, rectum, bladder and vagina in 38%, 86%, 76% and 
81% PTS respectively.Two PTS developed acute toxicities grade 3 (1 
acute diarrhea and 1 cystitis). One patient has vaginal dryness grade 3 
as a late sequel of RT. There were no toxicities greater than grade 3. 
 
Table 1. Median DVH Parameters of summed plans – Median 
Volume Percentage (Range) 
 V20  V30 V40 V50 V60 
Bladder 100 (88-
100) 
97 (71-
100) 
82 (82-
100) 
58 (14-
98) 
0 (0-39) 
Rectum 99 (89-100) 97 (88-
100) 
86 (75-
100) 
65 (13-
95) 
0 (0-45) 
Intestine 52 (29-74) 29 (15-42) 16 (5-31) 8 (0-19) 0 (0-2) 
 
Conclusions: The dose escalation is feasible and seems to have a 
satisfactory profile of toxicities. We succeed to fulfill the dose 
constraints comparable with those in the literature.  
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Purpose/Objective: 3D image based treatment planning has allowed 
examination of dose volume parameters rather than point doses in 
intracavitary brachytherapy (ICBT) of cervical cancer. The degree of 
bladder distension may change doses to organs at risk (OARs) & 
thereby incidence of complications. The purpose of the study was to 
assess impact of bladder volume on OARs wall doses during ICBT of 
cervical cancer patients. 
Materials and Methods: A prospective study performed in 10 patients 
with cervix cancer, stages II-III, treated by HDR-ICBT 600cGy / 
fraction for 3 fractions to Point A using conventional radiography 
based treatment planning. For dosimetric study all patients after 
insertion of ICBT applicator underwent pelvic CT scans with foley’s 
catheter in place (defined as empty bladder, EB) & thereafter 
injecting 300ml of normal saline in bladder, defined as full bladder 
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(FB). The delineation of OARs- bladder wall (BW), rectal wall (RW), 
sigmoid colon & bowel (peritoneal cavity) was done in both scans by a 
radiation oncologist. Both conventional & CT based planning were 
performed on PLATO brachytherapy planning system v14.3.7 
(Nucletron, The Netherlands). Dose volume histograms of OARs wall 
were calculated. The volume doses were defined either as minimum 
dose value in a cm3 volume receiving the highest dose (D0.1cc, D0.2cc, 
D0.5cc, D1cc, D2cc, D5cc, D10cc) or as percentage of volume of OAR 
receiving a dose (D25%, D50%, D100%). The significance of differences was 
compared using two sided paired t test. 
Results: The mean BW volume in EB & FB was 26.2cc (range 17.4-
40.4) & 44.8cc (range 38.5-49.2) respectively. When bladder was 
distended the mean difference in D0.1cc-10cc values for BW & RW 
increased marginally but were not statistically significant. However 
D0.1cc-10cc values for bowel dose (cGy) decreased significantly (0.1 cc. 
698.9 to 492.9 p=0.037, 0.2cc 666.4 to 465.7 p= 0.007, 0.5cc 617.7 to 
427.1 p=0.006, 1 cc 574.4 to 389.8 p=0.005, 2cc 521.4 to 347.9 
p=0.003, 5cc 446.4 to 286.7 p=0.002). In contrast the mean D25%, D50%, 
D100% values for both BW (411.3 vs 244.7, 254.6 vs 123.9, 78.6 vs 
26.2cGy) & bowel decreased (135.3 vs 81.2, 82.5 vs 51.6, 11.1 vs 
4.8cGy) when compared with EB &FB respectively which was 
significant at p=0.000 for all parameters for both OARs but no 
significant difference was seen for RW & sigmoid colon doses. 
Conclusions: Distension of bladder resulted in a significant reduction 
in bowel during image based ICBT without any significant increase in 
the dose to bladder wall, rectal wall and sigmoid colon and can be 
explored in clinical settings. 
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Purpose/Objective: The time course of human papillomavirus (HPV) 
DNA clearance was studied in patients with carcinoma of the cervix 
during follow-up after primary radical radiotherapy (RT). This study 
investigated the relationship between timing of HPV clearance and RT 
effectiveness. 
Materials and Methods: Seventy-two consecutive patients who were 
treated with primary radical RT for cervical cancer were enrolled in 
the study. Samples for HPV DNA examination were taken before: a) 
treatment, b) every brachytherapy, and c) and every follow-up 
examination. The times when HPV DNA was undetected were analyzed 
for association with recurrence free survival. 
Results: HPV DNA was not detected in 13 patients (18%) before RT. Of 
the 59 patients with HPV DNA detected before treatment, HPV DNA 
was not detected in 28% during treatment and in 72% after the 
treatment. Within six months after RT, HPV DNA was detected in 0% of 
all patients. Among the various time points analyzed, patients with no 
detectable HPV DNA before treatment were more accurate predictors 
of recurrence than patients with HPV DNA detected before RT. 
Conclusions: In this study we showed the time course of HPV DNA 
clearance during follow-up of patients with carcinoma of the cervix 
treated with primary radical RT. The patients in whom HPV was not 
detected had the worst prognosis. Six months after RT, HPV DNA was 
detected in 0% of the patients that had shown HPV DNA during 
treatment. In previous reports, those patients with HPV persistence 
after treatment would be considered a high risk group needing more 
effective or additional treatment. This study adds additional 
information on the relationship between detectability of HPV and RT 
effectiveness.  
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Purpose/Objective: We aim to retrospectively review the outcome of 
patients treated for EC with PORT at a single center. The secondary 
goals were identification of prognostic factors, comparison of toxicity 
profiles between vaginal cuff brachytherapy (VB) alone or combined 
with pelvic external beam radiation therapy and VB (EBRT+VB), and 
comparison of severe bladder and intestinal late toxicity (≥ G3) 
between 2D-, 3D-, and IMRT-EBRT+VB. We also investigate the 
incidence of second cancers.  
Materials and Methods: A series of 201 patients treated with PORT 
between 1999 and 2009. Patient's characteristics are summarized in 
table 1. Outcome, toxicity, and incidence of second cancers were 
confirmed by reviewing patient's charts. Overall survival (OS), 
locoregional control (LRC), disease-free survival (DFS), and cancer-
specific survival (CSS) curves were computed, and subgroups were 
compared via lograng test. Cox proportional hazards modeling was 
performed to evaluate the effect of multiple variables. 
 
Patient's characteristics Percentages (%) 
Median age 68 year-old   
Grade 1 32 
Grade 2 43.5 
Grade 3 24.5 
Lymphovascular invasion 32.5 
Stage (FIGO 1988)  
I A-B 28.85 
IC 30.85 
II 25.3 
III-IVA 15 
 
Results: At a median follow-up time of 5 years (range, 1-12), OS was 
78% (95% CI: 72-84%), DFS 72% (95% CI: 65-79%), CSS 84% (95% CI: 79-
89%), and LRC 84% (95% CI: 79-89%), In univariate analyses, significant 
prognostic factors for OS and DFS were age, grade, lymphovascular 
invasion (LVI), stage, cervical invasion, histology, and surgical 
lymphadenectomy. For CSS: histology type, cervical invasion, grade, 
stage, and presence of lymphovascular invasion. The use of 
brachytherapy was associated to better OS, DFS, and CSS in univariate 
analyses but its effect disappeared in multivariate analysis. In the 
multivariate analysis, independent factors influencing the outcome 
were age (OS, DFS), stage (OS, DFS, CSS), LVI (OS, DFS), grade (DFS, 
CSS), and lymphadenectomy (OS). By the end of follow-up, 13% of the 
patients developed severe GI or GU late toxicity, and the cumulative 
incidence of second cancers in the irradiated area was 16%. Five-year 
probability of severe (grade ≥ 3) toxicity was 0% for VB alone vs. 16% 
(95% CI: 9-23%) for EBRT+VB (p = 0.0008). By radiotherapy technique 
toxicity was: 0% for VB alone and 0% for IMRT+VB, 9% (95% CI: 1-17%) 
for 3D-EBRT+VB, and 22% (95% CI: 12-32%) for 2D-EBRT+VB, (p = 
0.0009).  
Conclusions: Local/locoregional recurrence rates remain low after 
surgery and PORT. The use of VB or EBRT+VB should be tailored to the 
surgical and pathologic features. Dependency between toxicity and 
radiotherapy technique is observed. VB alone or IMRT+VB have not 
provoked severe late toxicity. 2D-EBRT more than 3D-EBRT+VB was 
associated with increased severe toxicity. For patients with 
intermediate risk histopathologic features, VB alone seems to be 
sufficient. Comprehensive surgical staging with complete lympha-
denectomy impacts the outcome in this retrospective series. 
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Purpose/Objective: Carnitine palmitoyltransferase 1C (Cpt1c) is a 
brain-specific metabolic enzyme that is involved in energy 
homeostasis and appetite regulation (Wolfgang et al. 2006). We 
further identified Cpt1c as a gene regulated by the p53 transcription 
factor and by the AMP-dependent kinase (AMPK) (Sanchez-Macedo et 
al., accepted in CDD), which helps tumor cells to survive under 
metabolic stress, i.e. glucose deprivation and hypoxia (Zaugg et al. 
2011). To better understand the role of Cpt1c in tumorigenesis we 
need first to elucidate its physiological function, which is still unclear. 
We investigated the impact of loss of Cpt1c function in a mouse tumor 
model and analyzed the metabolic phenotype of a Cpt1c gene trap 
mouse. 
Materials and Methods: We used Nf1+/-:p53+/- mice as a tumor model. 
These Nf1;p53 heterozygous mice develop sarcomas with high 
frequency. These mice were crossbred with mice depleted of Cpt1c 
(Cpt1cgt/gt). The median survival rate of Nf1+/-:p53+/-:Cpt1cgt/gt mice 
was compared with Nf1+/-:p53+/- mice, Cpt1cgt/gt mice and a wild type 
control (C57BL/6 strain). Survival of the mice was plotted using a 
 
